Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective conventional TACE using porous glass membrane pump in hepatocellular carcinoma
jRCTs052200095Completed
- Sponsor
- PIOLAX Medical Devices
- Start
- Jan 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of epirubicin in hepatocellular carcinoma (HCC), sponsored by PIOLAX Medical Devices. Primary endpoint: Local complete response rate at 3 months. Started Jan 2021; status: completed.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs052200095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs052200095.